Jean‐Marc Nabholtz

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

Jean‐Marc Nabholtz, Aman U. Buzdar, Michaël Pollak et al. · Journal of Clinical Oncology · 2000 · 993 citations

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

Jean‐Marc Nabholtz, H.-J. Senn, W.R. Bezwoda et al. · Journal of Clinical Oncology · 1999 · 506 citations

Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate

Aman U. Buzdar, Joeri A J Douma, Nancy E. Davidson et al. · Journal of Clinical Oncology · 2001 · 363 citations

Growth Factors and Cytokines Upregulate Gelatinase Expression in Bone Marrow CD34+ Cells and Their Transmigration Through Reconstituted Basement Membrane

Anna Janowska‐Wieczorek, Leah A. Marquez‐Curtis, Jean‐Marc Nabholtz et al. · Blood · 1999 · 216 citations